Moderna, Inc.

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company founded in 2010 and headquartered in Cambridge, Massachusetts. The company went public in December 2018 and gained global prominence during the COVID-19 pandemic as one of the first companies to develop and commercialize an mRNA-based vaccine. Originally founded as Moderna Therapeutics, the company changed its name to Moderna, Inc. in August 2018. Today, Moderna has evolved from a single-product COVID vaccine company into a multi-product biotechnology firm with an expanding pipeline of mRNA-based therapeutics and vaccines across multiple disease areas.

Over the past few years, Moderna has undergone a significant strategic transformation from a pandemic-focused single-product company to a diversified mRNA therapeutics platform. The most notable development has been the company's evolution into a multi-product commercial entity with the 2024 approval and launch of mRESVIA, their RSV vaccine for adults, marking their second commercial product alongside the COVID-19 vaccine Spikevax. The company has aggressively pursued cost optimization initiatives, reducing operating expenses by $2.6 billion in 2024 and committing to an additional $1.4-1.7 billion in cost reductions by 2027. This includes streamlining their pipeline focus to approximately 10 high-value programs with near-term approval potential, winding down less promising Phase 3 trials, and optimizing manufacturing operations. Pipeline advancement has been substantial across multiple therapeutic areas. In respiratory vaccines, Moderna has filed for FDA approval of their next-generation COVID vaccine, received positive Phase 3 results for their seasonal flu vaccine, and submitted a combination flu-COVID vaccine for regulatory review. The company has also expanded their RSV vaccine indication to include high-risk adults aged 18-59. In oncology, Moderna has significantly expanded their Individualized Neoantigen Therapy (INT) program beyond melanoma into multiple cancer types, reporting sustained three-year follow-up data showing continued efficacy when combined with Merck's Keytruda. The company is preparing for potential accelerated approval pathways and expanding manufacturing capabilities for personalized cancer vaccines. The rare disease portfolio has shown encouraging progress, with their Propionic Acidemia program selected for FDA's START program and early positive results in Methylmalonic Acidemia treatment. Additionally, Moderna has lifted clinical holds on their Norovirus vaccine program and continues advancing their high-value CMV vaccine through Phase 3 trials. Manufacturing and commercial expansion has included establishing international production capabilities in the UK, Canada, and Australia, while transitioning from government contract sales to commercial pharmacy-based distribution models globally.